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ABSTRACT
Clinical trials are the standard for identifying new drugs for the treatment of disease, but re-
sults are dependent on patient compliance. The success of treatments for HIV disease in par-
ticular may be judged in part by their effect on immunologie, virologie, or clinical measures
collected on patients at regular predefined intervals. If patients drop out of a trial before study
completion, the analysis of the repeatedly collected parameters needs to be undertaken and
interpreted with care. The authors recommend using graphic techniques to assess the impact
of the missing data on the profiles of the parameters over time. To assess treatment differ-
ences, a variety of simple tests are proposed that allow different assumptions to be made re-
garding the reasons for the incomplete data. A case study is presented providing an analysis
of CD4 data from the Pédiatrie Aids Clinical Trials Group (PACTG) Protocol 051, in which
only 52% of the patients completed the study while remaining on treatment; younger patients
with lower CD4 counts were more likely to stop treatment earlier. This type of systematic
missing data can lead to incorrect conclusions regarding different treatment effects on CD4
counts. With the data of PACTG 051, however, regardless of the methodology used, no treat-
ment differences were found. Inconsistent conclusions would have indicated the need for
more sophisticated statistical techniques to adequately test for treatment differences.
INTRODUCTION
Although clinical Endpoints are usuallythe measure of choice for assessing the ef-
ficacy of new drugs, the progression of HIV
disease may take many years, sometimes mak-
ing it impractical to design trials with these out-
comes. Even when clinical endpoints are of pri-
mary interest, immunologie function, viral
load, or, in children, growth and neuropsy-
chologic function are often collected for sec-
ondary analyses. In the design stage of a trial,
it may not be known exactly how, when, or by
how much the treatment will impact these sec-
ondary parameters. As a result, researchers
plan the collection of measurements at prede-
termined points of time during the study in an
attempt to capture the differential effects of the
study treatments.
Frequently, not all patients have the same
number of measurements at the end of a study.
The time of a patient's last measurement is
called their "censoring" time. Patients may be
enrolled over several months and followed un-
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til a specific date. Patients enrolled earlier are
followed for a longer time and consequently
have more assessments. If the only reason for
stopping data collection is trial closure, then
standard statistical techniques are appropriate
to assess treatment differences in the repeat-
edly collected parameters. However, patients
may also either stop treatment prior to study
closure or leave the study due to an inability to
tolerate the drug, lack of efficacy, or for reasons
unrelated to the drug protocol or the individ-
ual's medical status. Some studies also may fail
to collect data regularly on patients who stop
treatment, even when they remain within the
study, and no data can be collected on patients
who leave the study completely. The reasons
behind the censoring time (also termed the
"missing data mechanism") can be compli-
cated. If there are systematic reasons, related
either to the outcome of interest or to the study
treatment, simple analyses for treatment dif-
ferences can be misleading. This article ad-
dresses this data-collection problem and offers
a simple approach for analysis of study data
with incomplete repeated measures.1^1 The
immunologie marker CD4 collected in the Pé-
diatrie AIDS Clinical Trials Group (PACTG)
Protocol 0515 is used to illustrate this problem
and the suggested graphic and analysis tech-
niques.
PATIENT DROP-OUT
In most clinical trials, patients are followed
while receiving the study treatment and con-
tinue to be followed if they are taken off treat-
ment until the study closes. Usually, the fre-
quency of patient visits and the types of
assessment decrease when patients are off
treatment but still followed in the study. There
are two approaches to analysis. An "explana-
tory" analysis uses data collected only while
patients are receiving treatment. The objective
is to determine true treatment differences un-
der perfect compliance. In contrast, a "prag-
matic" analysis uses all data collected from pa-
tients who are both on and off treatment. This
approach is closer to an "intent-to-treat" or
"real-life" approach, assessing the treatment
differences when applied to a population that
practices imperfect compliance. A problem
with the explanatory analysis is that compli-
ance may be related to treatment effect4 with
good compliance resulting in a better response
than bad, a result that may occur even if all
study participant were given a placebo. This
can make interpretation of treatment differ-
ences problematic. Most analysts prefer the in-
tent-to-treat approach, but it requires following
patients and collecting data from them until the
study closes, whether they are still receiving
treatment or not. With intent-to-treat analyses,
treatment comparisons must be undertaken
with care, especially when data collection
ceases after a patient goes off treatment or if
patients drop out of the study before study clo-
sure.
We will refer to three general types of "miss-
ing data" following the terminology of Little
and Rubin,6 and focus on data missing due to
patient dropout. CD4 counts in a clinical trial
reflect the immunologie status of the patient,
with sicker patients having lower counts. It is
thought that treatments that can increase or at
least maintain CD4 counts will benefit the pa-
tient, so treatment comparisons of CD4 are usu-
ally of interest, even when the primary end-
point of the study is disease progression or
death. In the first type, if data collection is
stopped for reasons unrelated to the CD4 count(e.g., study closure, or moving to another state),
data will be "missing completely at random"(MCAR), meaning that the "missingness" of
the data is unrelated to the outcome of interest
and the censoring is "noninformative". Sum-
mary counts of the CD4 measurements for the
patients on study should be representative of
the entire study population because the reasons
patients are going off study are unrelated to
their CD4 counts. Most analyses will not be af-
fected by this kind of missingness, even if it is
associated with treatment; for example, if one
drug were more toxic than another possibly
causing patients on the more toxic treatment to
stop treatment sooner. The second type of miss-
ing data is data "missing at random" (MAR)
when patients drop out of the trial for reasons
related to the outcome of interest observed to
that point. In the CD4 example, patients might
be switched to a different treatment if their CD4
count dropped below 200 cells/mm3. In this
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case, patients remaining on the study treatment
will by definition have CD4 counts above 200
and those who are off the treatment CD4 counts
below 200. Median CD4 counts of the patients
on treatment would be higher over time than
would be observed if the data from the patients
off treatment had been included, and therefore
are not representative of the entire study pop-
ulation. When data are MAR, the censoring
mechanism is still noninformative. The third
type of missing data is "nonignorable" and the
censoring "informative." This occurs when pa-
tients drop out of the trial for reasons that de-
pend not only on the observed data to the point
of drop-out, but also on the data that would
have been collected after they were lost from
the trial. An example would be a patient who
started the trial with a CD4 count of 500
cells/mm3 and at each of 2 subsequent visits
their count decreased by an additional 100
cells/mm3 and would continue to drop if they
remained on the original treatment. As with the
MAR case of missing data, summary counts of
the CD4 measurements for patients remaining
on treatment would not be representative of the
counts that would have been observed for the
entire study population. There is a vast body
of literature describing types of missing data
and their impact on modeling and testing.1-4'6'7
The point to be emphasized here is that the an-
alyst must be aware of the potential for infor-
mative censoring and other different censoring
patterns dependent on the treatment group(differential censoring) as well as how the in-
teraction of these two phenomena may affect
treatment comparisons related to the outcome
of interest.
AN EXAMPLE: CD4 COUNTS IN
PACTG 051
We illustrate the analyses using CD4 data
collected in the PACTG Protocol 051 trial.5
PACTG 051 was a randomized trial designed
to compare prophylactic intravenous immuno-
globin (IVIG) with placebo in symptomatic
HIV-infected children being treated concur-
rently with zidovudine (ZDV) for the preven-
tion of serious bacterial infections. A margin-
ally significant reduction in time to first serious
bacterial infection was seen in the IVIG group(p = 0.07). Secondary analyses of interest in-
cluded survival and the impact of the two treat-
ment regimens on CD4 counts over time. In ad-
dition to intermittently missing data due to
missed visits and off-schedule visits, CD4 data
were only collected while the patients were re-
ceiving the study treatment (either IVIG or
placebo). Only 133 of the 255 évaluable patients
remained on treatment at study closure. Forty-
one patients had died, 13 experienced drug-re-
lated adverse events, and 7 stopped treatment
for lack of efficacy; the remainder dropped out
of the trial for reasons likely unrelated to the
study drug. Because patients were taken off the
study treatment for failing efficacy and by de-
finition death, and because declining CD4
count may be related to increased susceptibil-
ity to serious bacterial infections or death, it is
possible that the immunologie data are either
MAR or informatively censored. Times on
study treatment and survival are comparable,
but it will also be important to consider the pos-
sibility of differential censoring by treatment
group, i.e., patients coming off either IVIG or
placebo at different rates. Note that because
CD4 was only collected while patients were on
the study treatment, an explanatory analysis
would be straightforward, but potentially af-
fected by compliance. The imputation methods
suggested in the graphic techniques that follow
allow one to consider how the data might have
appeared if collection had continued after pa-
tients went off treatment, this in an attempt to
approximate an intent-to-treat analysis.
GRAPHIC DISPLAYS
Graphic displays can be a useful exploratory
tool to check for the existence of informative
and differential censoring in a data set with re-
peatedly measured outcomes. The discussion
above already recognizes the plausibility of pa-
tients with lower CD4 counts being taken off
treatment at higher rates has already been rec-
ognized in the discussion above, but can be ex-
plored further using displays. The first of two
display examples is a simple plot of summary
statistics over time adjusted to account for pa-
tients going off study treatment. The second is
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a less traditional "tracking display" (personal
communication, R.D. Gelber) which presents
summaries of the parameter of interest over
time for patients remaining on the study treat-
ment and those lost to the study treatment; it
also tracks summary statistics on additional
characteristics of the patients. Examples of each
graphic display using the PACTG 051 data are
shown in Figures 1 and 2.
Graphs of summary statistics
Figure la shows the observed median CD4
counts up to week 100 for the two treatment
groups in the PACTG 051 trial. Because pa-
tients did not always come in at the scheduled
visit times as determined by the protocol, the
data are grouped into windows formed around
these visit times. Medians are chosen as the
summary statistic because CD4 tends to be
skewed and means are sensitive to outlying ob-
servations. Ideally, a measure of the variability
also should be given by including lines for the
lower and upper quartiles of the grouped data
on the graph. The impression from this graph
using only available data is that the IVIG group
starts with a somewhat lower CD4 count and
decreases a little more than the placebo group
until week 50 but the two groups then return
to similar levels. The differences at baseline be-
tween the two groups can be explained by the
IVIG group having slightly but not signifi-
cantly older children (p = 0.10 from a two-sam-
ple Wilcoxon test). CD4 counts in children are
highly dependent on age, with newborns hav-
ing much higher values that decrease to adult
levels by about 12 years.8
Figure la includes only the patients on treat-
ment. If data had been collected off treatment
but on study (thus allowing an intent-to-treat
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FIG. 1. a: Graphic display of CD4 median counts by treatment from the Pédiatrie AIDS Clinical Trials Group Pro-
tocol 051 (PACTG 051). —, placebo,-, IVIG. b: Death -» CD4 = 0 fills in 0 for all patients known to have died,
leaving others as missing, c: LVCF fills in last known value for a patient, d: LVCF, death -» CD4 = 0 fills in 0 for all
patients known to have died and the last known value for all patients lost to follow-up for other reasons.
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FIG. 2. PACTG 051: Tracking display of CD4 cells/mm3
and age (years) using LVCF which fills in last known
value for a patient if missing at each visit. Solid lines rep-
resent patients on treatment. Dotted lines represent pa-
tients lost to follow-up.
analysis), and if CD4 count is indeed related to
the overall health of the child, the curves would
likely have decreased more over time because
the patients going off treatment would have
lower CD4 counts. Figures lb-d show what the
curves might have looked like if CD4 had been
collected by including "imputed" CD4 counts
for the patients going off study treatment. The
lines in Figure lb are generated by substituting
the value 0 for the CD4 measurements at all
visits after the patient died. In Figure lc, the
patient's last known CD4 measurement is sub-
stituted for all visits after the patient went off
treatment. This is known as the "last value car-
ried forward" (LVCF) approach.9 Values are
left as missing if the patient is still being fol-
lowed on treatment but missed a visit for an-
other reason. Lines in Figure Id are derived by
substituting the last known value for all miss-
ing data (intermittent and for patients going off
treatment), and the value 0 if the patient dies.
This tends to smooth the curves because the
sample sizes are the same at all time points. Im-
puting 0 for deaths provides additional infor-
mation if (a) the number or timing of the deaths
is different in the two treatment groups or (b)
if the survival patterns are the same but the tim-
ing or value of the last CD4 measurement is dif-
ferent. This might occur if patients on one treat-
ment group tended to stop treatment earlier
with higher CD4 counts (differential censor-
ing), but there were no differences in their ul-
timate survival.
Figures lb and c show more of a decrease in
CD4 through the first 100 weeks of the study
than in Figure la, confirming that it is the pa-
tients with lower CD4 who are going off the
study treatment and that the data are not
MCAR. Note the difference in the separation of
the curves between Figures la and c. Looking
only at Figure la, one might conclude there are
no treatment differences after week 60, but Fig-
ure lc shows a consistent treatment difference
over 100 weeks. This illustrates the potential for
incorrect conclusions from treatment compar-
isons that ignore the missing data mechanism.
As expected, the CD4 counts in Figures lb
and d drop more over time than in Figures la
and c because the value 0 is being imputed for
the patients who died. The placebo curve
shows somewhat more of a decrease than the
IVIG curve, which suggests the potential for
differential censoring with respect to CD4. Be-
cause there were no differences between the
survival curves or times to when patients came
off treatment, this may be an artifact of the
slightly different ages of the groups at baseline.
These kinds of graphs also can be displayed
by important covariates. In pédiatrie AIDS clin-
ical trials, it is not uncommon for study treat-
ments to differentially affect the younger chil-
dren.10 Repeating the above displays by age
group would not only show the impact of age
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on the CD4 profiles over time, but also high-
light any differences in the time to off study
treatment for the two treatment groups within
the age groups.
We do not advocate the use of the LVCF ap-
proach in formal treatment comparisons or for
estimating the CD4 counts over time, but only
as a way of assessing the impact of informative
or differential censoring. As discussed in nu-
merous articles,1'9,11'12 even if the data are
MCAR, under certain conditions, if one group
is losing patients more rapidly than the other,
the LVCF curves may give a biased picture.
Also of concern is the fact that the curves are
not representing "real" data, so it is difficult to
interpret the estimated counts.
Tracking display
The graphic display in Figure 2 shows how
additional information can be tracked on the
characteristics of the patients remaining on the
study treatment and those going off the treat-
ment. In this example, we consider the age of
the patients as well as their CD4 count. The
summary statistics are enclosed in a box rep-
resenting the total number (100%) of patients
randomized at baseline in each group (126
placebo patients and 129 IVIG patients). The
area enclosed by dashed lines represents the
growing proportion of patients on whom CD4
data are no longer being collected. The column
"Actual" shows the median CD4 count and
ages (in years) of the patients still on the study
treatment (with the last value carried forward
for intermittently missing observations). The
column "LVCF" shows the median of the last
CD4 counts measured on the patients when
they were taken off treatment and their median
ages calculated at each study week.
In the PACTG 051 trial, about 40% of patients
dropped out in both treatment groups by week
100 (the area enclosed by the dashed lines is
about 40% of the total area of the box at week
100). The patients dropping out (whose data
are summarized in the LVCF column) are
younger (median age in LVCF column is less
than median age in Actual column) and have
lower imputed CD4 count, than do the patients
remaining on treatment; this implies that it is
the patients with lower CD4 counts who are be-
ing taken off treatment, and the data are most
likely not MCAR. Because the pattern of miss-
ingness is similar in the two treatment groups,
however, the censoring does not depend on
treatment, so there is no evidence of differen-
tial censoring.
In summary, both graphic displays provide
evidence that the patients with lower CD4
counts are more likely to stop treatment early,
so the data are not MCAR. The summary
curves suggest CD4 counts in the placebo
group might be decreasing faster than the IVIG
group due to differential censoring, but the ef-
fect is minimal and may be an artifact of the
slightly higher age of the placebo group at the
beginning of the study. Because the missing
data are impacting the CD4 profiles over time,
the possibility of misleading results in the tests
for treatment differences from standard statis-
tical methods needs to be considered. The fol-
lowing discussion includes three approaches to
testing and a comparison of the results using
the PACTG 051 trial data. Detailed results are
not presented in this article but are available
from the authors.
AN APPROPRIATE METHOD WHEN
DATA ARE MCAR
The most straightforward analysis for differ-
ences in treatment effects on a parameter with
repeated measures is the t test (if the data are
normally distributed) or a nonparametric test(which makes no assumptions about how the
data are distributed) such as the Wilcoxon test
at each time point or on changes from base-
line.13 This approach not only assumes that the
data are MCAR (i.e., the observed CD4 counts
are representative of the entire study popula-
tion), but if measurements are taken at multi-
ple time points, results may be difficult to in-
terpret if results at some time points and not at
others are statistically significant. As the num-
ber of tests increases, the probability of a spu-
rious statistically significant result increases,
and methods to account for these multiple com-
parisons must be considered.13 Repeated-mea-
sures analysis of variance14 is one technique
that is available in most standard statistical
software packages. These assume that data are
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normally distributed, and some require the raw
data on each patient to be grouped by visit. Un-
til recently, however, many packages did not
allow for any missing data.
As an alternative, we suggest a nonparamet-
ric method proposed by Wei and Lachin15 and
expanded upon by Wei and Johnson.16 This
procedure uses the ranks of the data points
rather than the actual values, so the data can
be skewed (as is the case with CD4 measure-
ments) without biasing the test results. The
method requires data to be MCAR, but the
missingness patterns can be different across
treatment groups. It has the advantage of pro-
viding a single test statistic for the repeated
measures, circumventing the problem of mul-
tiple comparisons. The method cannot accom-
modate other covariates explicitly, but separate
analyses can be done for subgroups of patients.
Given k repeated measures from two treat-
ments, a test of the null hypothesis (the distri-
bution of the parameter of interest in the two
treatments is the same), can be done as follows.
Tests such as the Wilcoxon rank sum test are
calculated at each time point as are the covari-
ances between the statistics. Wei and Lachin15
combine the k tests into a summary statistic that
can be compared to a x2 distribution with k de-
grees of freedom. If a difference is found be-
tween the treatments in this overall test, there
are ways of testing hypotheses within subsets
of time points to identify when the differences
occurred. Because the summary test is de-
signed to look for different patterns in the treat-
ment profiles, it may not be powerful enough
to detect the specific case where patients on one
treatment are consistently doing better than
those on the other treatment at all time points.
In this case, another "univariate" test statistic16
can be calculated that will be more likely to de-
tect a difference between treatments.
In applying this method to the CD4 data
from the PACTG 051 trial, we suspect from the
graphic displays that the data are not MCAR,
so the results of this analysis should be viewed
with suspicion. The method will be one step in
our approach of performing a number of dif-
ferent analyses, making different assumptions
about the missing data mechanism. The data
are grouped into study weeks as for the graphic
displays, based on the scheduled data collec-
tion times defined in the research protocol. The
individual one-sided significance levels from
Wilcoxon tests comparing CD4 counts in the
two treatment groups at the seven time points
at weeks, 4, 12, 28, 44, 60, 76, and 100 are p =
0.49, 0.25, 0.10, 0.09, 0.23, 0.39, and 0.46, re-
spectively; none are significant at the 5% level.
The summary test is also nonsignificant at the
5% level (p = 0.55). Because the placebo curve
lies above the IVIG curve at all time points (Fig.
la), the univariate statistic will be more pow-
erful in detecting a treatment difference if it ex-
ists. The result from the univariate test is more
significant than the summary test but even so
does not reach the 5% significance level (p —
0.23). The conclusion is that there are no treat-
ment differences in CD4 counts over time.
AN APPROPRIATE METHOD WHEN
DATA ARE MAR
An alternative to the approach by Wei and
Johnson,16 who calculate test statistics at each
time point and then combine them into a sin-
gle summary test statistic, is to calculate one
summary measure for each patient's data
throughout the clinical trial and use it to form
a test for treatment comparisons. Depending on
the statistic chosen, this approach to an analy-
sis can be valid not only when the data are
MCAR but when the data are MAR, and under
some conditions even when the data are infor-
matively censored.17-19
The time at which treatments are expected to
affect the parameter of interest will determine
the choice of summary measure. If the analyst
hypothesizes a gradual effect over time, then a
reasonable choice is to calculate a slope as the
summary measure for each patient or to calcu-
late the difference between the first few mea-
surements and the last few measurements. If
the effect of treatment is expected to occur early(e.g., week 12) and then be maintained while
the patients are on treatment, differences be-
tween baseline values and the onset of the treat-
ment effect (e.g., week 12) would be the best
choice. Dawson and Lagakos17'18 discuss addi-
tional considerations for the best choice of sum-
mary measure. In the example of the PACTG
051 trial, slopes are reasonable because the
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sicker patients should have steeper downward
slopes than the healthier patients, and the
graphic summaries suggest gradual decreases
over time rather than sharp drops. The slope
statistic has the additional advantage that, un-
der certain conditions, it may give unbiased es-
timates and treatment comparisons, even when
data are informatively censored.17-19
Calculation of the slope
For each individual i, a slope, ß\, is calculated
based on the line:
/ogio(CD4+) = oí + ßiWeek, i = 1,..., n.
The slope will be estimated with more preci-
sion for the patients with more observations.
However, the sicker patients will likely have
steeper declines and fewer observations be-
cause they will be more likely to drop out of
the study. These patients receive equal weight
to those calculated on the patients with stable
CD4 who do not drop out of the study.
Schluchter19 refers to this approach as the un-
weighted least-squares estimate and explains
that it is an unbiased estimate of the popula-
tion slope (the slope that would have been ob-
served with no patient drop-out) even under
informatively censored data, as long as all pa-
tients have at least two measurements.
For the example, all available data are used
from week 4 onwards. Only patients with at
least two measurements can be included in the
analysis, which reduces the number of patients
from 255 to 236. When interpreting the results,
it is important to understand that the subset of
patients included in the analysis may not be rep-
resentative of the entire group. In this example,
the excluded patients were younger at random-
ization (2.3 years versus 3.8 years) and had
slightly lower CD4 counts (332 cells/mm3 ver-
sus 374 cells/mm3). This selection means an un-
biased estimate of the full population slope can-
not be guaranteed19 unless the data are MAR.
Simple testing for treatment differences
Once a summary measure has been calcu-
lated for each individual, the simplest way to
test for treatment differences is the usual two-
sample t test or nonparametric Wilcoxon com-
parison. If data are MAR and there is no dif-
ferential censoring, the test based on the least-
squares slopes will be valid. Histograms of the
slopes for the PACTG 051 data show some out-
lying observations, so nonparametric tests are
used to compare the slopes in the two treat-
ment groups. An overall test across all age
groups shows no difference between treatment
groups (p = 0.40). We repeat the treatment
comparisons within age groups 0 to 1 years, 1
to 2 years, 2 to 6 years, and over 6 years be-
cause of the initial imbalance in ages at ran-
domization, and the fact that the slopes are age
dependent. Within each age group there are no
significant treatment differences.
Testing adjusting for other important factors
Tests for treatment comparisons can be bi-
ased if there are other important variables af-
fecting the outcome of interest that are not bal-
anced by treatment group. Although the two
sample tests in the previous section can be re-
peated within subgroups (as was done with age
in the previous section), this will become im-
practical if there are many covariates. In this
case, the summary measure can be analyzed us-
ing standard analysis of variance (ANOVA).13
This procedure is relatively insensitive to vio-
lations of the underlying assumptions despite
being a parametric procedure, and there are
well-known techniques for checking the as-
sumptions that are made.20
Potentially important covariates that are
thought to affect declines in CD4 counts are
prophylaxis for Pneumocystic carinii pneumonia
at baseline, prior use of ZDV at baseline, and
age. Controlling for these three covariates, the
test for study treatment differences on the rate
of decreasing CD4 counts is again not signifi-
cant at the 5% level.
AN APPROPRIATE METHOD WHEN
DATA ARE INFORMATIVELY
CENSORED
Data that are informatively censored are the
most difficult to interpret, and much research
is being done in this area. Good reviews are
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given by Diggle and Kenward2 and Little.3
Most methods require modeling the missing
data mechanism with sophisticated computa-
tion beyond the scope of this article. In keep-
ing with our aim of suggesting a range of sim-
ple analyses, we focus on the methodology of
Dawson and Lagakos,17'18 who extend the two
sample test for treatment differences used in
the previous section to tests valid under infor-
mative censoring.
The extension proposed by Dawson and La-
gakos is that if the data are not MCAR or MAR,
valid treatment comparisons can be done by
stratifying the analyses by the missingness pat-
tern and perhaps by the reasons for missing-
ness. The data must be grouped into visit
weeks, as was done for the graphic displays
and the Wei and Johnson16 analysis, and then
grouped again by type of missingness (infor-
mative or random) and missingness pattern(patients missing data at the same visits are
grouped together). Within each group or stra-
tum, a test statistic, Zg, is calculated using a
Wilcoxon test, for example. The overall test for
treatment differences is formed using a
weighted combination of the Zg, which can be
compared with a standard normal distribution.
Dawson21 discusses the actual behavior of the
stratified and unstratified (as in the previous
section) tests under a variety of conditions. The
disadvantage of this approach is that the num-
ber of strata formed can be large when a trial
extends for a long period of time and there are
many different patterns of missing data. This
is the case for the PACTG 051 trial data, where
it is impractical to stratify by the complete set
of missingness patterns. To illustrate the
methodology, however, we constructed four
strata defined by whether patients stopped
treatment before or after week 44 and whether
the reason treatment was stopped was death.
The overall test has a p value of 0.93. This non-
significant result is consistent with all previous
analyses.
DISCUSSION
In clinical trials of new treatments for AIDS,
data on immunologie, virologie, and other clin-
ical measures are often collected at regularly
scheduled times. An intent-to-treat analysis
that looks at treatment efficacy under imper-
fect but more realistic compliance is usually
preferred, but treatment comparisons will be
complicated by missing data due to patient
drop-out. The simplest way to avoid this prob-
lem is for protocols to call for the collection of
all parameters whether participants are being
administered treatment or treatment has been
stopped, and to make every effort to follow all
patients during the course of the trial. If this is
not possible, care must be taken in the analy-
sis and interpretation of the data collected over
time, with particular attention directed to the
potential problems from patient drop-out. If
the patients remaining within the study are not
representative of the entire study population,
treatment comparisons based only on the ob-
served data may be incorrect. An explanatory
analysis is possible even if data are not col-
lected after patients stop treatment, but inter-
pretation of the results can be complicated by
issues such as patient compliance.
Although there are sophisticated methods
available for the analysis of informatively cen-
sored data, we suggest an approach using more
straightforward exploratory and analytic tech-
niques. In some cases these methods may be
sufficient; if they are not, it should alert the an-
alyst to the need for the more complicated
methods. Initially, graphic displays are used to
assess whether there is informative or differ-
ential censoring and for tracking the character-
istics of patients whose data are no longer be-
ing collected. In the PACTG 051 study, the
younger patients with lower CD4 counts were
more likely to stop study treatment and have
prematurely censored CD4 data collection. This
meant that the profiles of CD4 data for the pa-
tients remaining on the study treatment were
not necessarily representative and probably ar-
tificially higher over time than would have
been observed if the CD4 values of the entire
population had continued to be measured. Dif-
fering separations of the curves over time were
seen by imputing the last observed CD4 count(LVCF) for patients going off the study treat-
ment and imputing the value 0 for those pa-
tients who died. Simply applying standard sta-
tistical tests for treatment differences at specific
time points could lead to different results, de-
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pending on what values were imputed. To as-
sess the sensitivity of the tests for treatment dif-
ferences to the missing data assumptions, we
suggested using three approaches and com-
paring the results.
The method of Wei and Johnson16 provides
one statistical test for simultaneously compar-
ing the parameter of interest at multiple time
points (and thus avoiding the problems of mul-
tiple testing) and a more powerful test if one
group is consistently superior to the other. This
nonparametric test makes few distributional
assumptions, but does require the data to be
MCAR. Summary statistics, such as individual
slopes, are useful for simple testing and can be
adjusted for other covariates in a standard
ANOVA. Testing of individual slopes can be
conducted if the data are informatively cen-
sored by stratifying according to the types and
timing of the missing data and calculating a
suitably adjusted summary test statistic. For
the PACTG 051 data, all of the methods failed
to show any statistically significant differences
so we can be comfortable with the conclusion
that there were no treatment differences in CD4
counts over time in this study. Inconsistent
findings would have pointed out the need for
more sophisticated methods.
Researchers need to be aware of potential bi-
ases in analyses of data from clinical trials with
patient drop-out. There are usually systematic
reasons why patients do not complete a study,
often related to the outcome of interest. Con-
clusions from any trial with patient drop-out
need to be made with care, acknowledging that
the patients who complete the trial may not be
representative of the population who enrolled.
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